SCP Vitalife seeks to invest in early- to mid-stage stage life science companies with exceptional technology or other proprietary advantages that are poised to capitalize on major market trends. The Fund’s target initial investment size is $3-$7 million, with a typical total investment of $7-$15 million over the lifespan of the investment.
SCP Vitalife believes that Israel presents an excellent source of life science technology investment opportunities, particularly in the field of medical devices. The Israeli life science industry has experienced exceptional growth during the past decade, and is a global leader in life-sciences patents-per-capita.
With an office in Tel-Aviv, Israel, the Fund has created, and will be able to draw upon, its strong relationships with Israel's renowned academic institutions and its unique network of relationships with key technology sources in the Israeli defense industry.
SCP Vitalife allocates over half of its investment capital to investments in Israeli companies, or to companies that have significant R&D and operational ties to Israel. The remainder of the Fund’s investment capital is allocated to companies based in the U.S.